Eisai Gains Orion's Branded Generics Fareston And Eldepryl For China; Oncology Sales Force Can Be Seen In Action In Advance Of Halaven
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai Inc. is tapping into China's opportunities for branded generics. The company announced July 13 it acquired marketing and distribution rights for Orion Corp.'s breast cancer drug Fareston (toremifene) and Parkinson's disease drug Eldepryl (selegiline), both of which are available as generics in China